» Articles » PMID: 36176446

Identification and Verification of Hub Genes Associated with the Progression of Non-small Cell Lung Cancer by Integrated Analysis

Overview
Journal Front Pharmacol
Date 2022 Sep 30
PMID 36176446
Authors
Affiliations
Soon will be listed here.
Abstract

Lung cancer is one of the most common cancers worldwide and it is the leading cause of cancer-related mortality. Despite the treatment of patients with non-small cell lung carcinoma (NSCLC) have improved, the molecular mechanisms of NSCLC are still to be further explored. Microarray datasets from the Gene Expression Omnibus (GEO) database were selected to identify the candidate genes associated with tumorigenesis and progression of non-small cell lung carcinoma. The differentially expressed genes (DEGs) were identified by GEO2R. Protein-protein interaction network (PPI) were used to screen out hub genes. The expression levels of hub genes were verified by GEPIA, Oncomine and The Human Protein Atlas (HPA) databases. Survival analysis and receiver operating characteristic (ROC) curve analysis were performed to value the importance of hub genes in NSCLC diagnosis and prognosis. ENCODE and cBioPortal were used to explore the upstream regulatory mechanisms of hub genes. Analysis on CancerSEA Tool, CCK8 assay and colony formation assay revealed the functions of hub genes in NSCLC. A total of 426 DEGs were identified, including 93 up-regulated genes and 333 down-regulated genes. And nine hub genes (CDC6, KIAA0101, CDC20, BUB1B, CCNA2, NCAPG, KIF11, BUB1 and CDK1) were found to increase with the tumorigenesis, progression and cisplatin resistance of NSCLC, especially EGFR- or KRAS-mutation driven NSCLC. Hub genes were valuable biomarkers for NSCLC, and the overexpression of hub genes led to poor survival of NSCLC patients. Function analysis showed that hub genes played roles in cell cycle and proliferation, and knockdown of hub genes significantly inhibited A549 and SPCA1 cell growth. Further exploration demonstrated that copy number alterations (CNAs) and transcription activation may account for the up-regulation of hub genes. Hub genes identified in this study provided better understanding of molecular mechanisms within tumorigenesis and progression of NSCLC, and provided potential targets for NSCLC treatment as well.

Citing Articles

Targeting Kinesins for Therapeutic Exploitation of Chromosomal Instability in Lung Cancer.

Zhang C, Wu B, Thu K Cancers (Basel). 2025; 17(4).

PMID: 40002279 PMC: 11853690. DOI: 10.3390/cancers17040685.


POU4F1 enhances lung cancer gemcitabine resistance by regulating METTL3-dependent TWF1 mRNA N6 adenosine methylation.

Tang J, Liu Z, Xie G, Wang C, Jiang Y 3 Biotech. 2024; 15(1):7.

PMID: 39676891 PMC: 11638459. DOI: 10.1007/s13205-024-04161-w.


Exploring common pathogenic association between Epstein Barr virus infection and long-COVID by integrating RNA-Seq and molecular dynamics simulations.

Kanwal A, Zhang Z Front Immunol. 2024; 15:1435170.

PMID: 39391317 PMC: 11464307. DOI: 10.3389/fimmu.2024.1435170.


Eg5 and Diseases: From the Well-Known Role in Cancer to the Less-Known Activity in Noncancerous Pathological Conditions.

Ricci A, Carradori S, Cataldi A, Zara S Biochem Res Int. 2024; 2024:3649912.

PMID: 38939361 PMC: 11211015. DOI: 10.1155/2024/3649912.


Identifying lncRNAs and mRNAs related to survival of NSCLC based on bioinformatic analysis and machine learning.

Yue W, Wang J, Lin B, Fu Y Aging (Albany NY). 2024; 16(9):7799-7817.

PMID: 38696317 PMC: 11131976. DOI: 10.18632/aging.205783.


References
1.
Drilon A, Siena S, Ou S, Patel M, Ahn M, Lee J . Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017; 7(4):400-409. PMC: 5380583. DOI: 10.1158/2159-8290.CD-16-1237. View

2.
Schafer J, Lehmann B, Gonzalez-Ericsson P, Marshall C, Beeler J, Redman L . Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors. Sci Transl Med. 2020; 12(534). PMC: 7427123. DOI: 10.1126/scitranslmed.aaw8275. View

3.
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

4.
Dummer R, Lebbe C, Atkinson V, Mandala M, Nathan P, Arance A . Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nat Med. 2020; 26(10):1557-1563. DOI: 10.1038/s41591-020-1082-2. View

5.
Gyorffy B, Surowiak P, Budczies J, Lanczky A . Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 2013; 8(12):e82241. PMC: 3867325. DOI: 10.1371/journal.pone.0082241. View